https://www.thebodypro.com/author/treatment-action-group

Latest by Treatment Action Group

Latent HIV Reservoirs Appear to Be Reactivated by Compound Found in Plant Img

Latent HIV Reservoirs Appear to Be Reactivated by Compound Found in Plant

Ingenol B (Ing B), a compound found in a tropical plant, shows promise in reactivating the latent HIV reservoirs. More research on the compound could provide innovative approaches to eradicate the virus.

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug Img
News Analysis

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug

HCV drugs are priced out of reach and out of control.

-- Michel Sidibé, UNAIDS

MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...

Introducing the 2014 Pipeline Report on HIV, Hepatitis C Virus (HCV) and Tuberculosis (TB) Img
Hepatitis C

Introducing the 2014 Pipeline Report on HIV, Hepatitis C Virus (HCV) and Tuberculosis (TB)

Last year we wrote:

[Getting] the best drugs to the most people as quickly as possible ... requires that the compounds and combination products be:

Discovered and developed in a high-quality research program; Approved by a national or multinati...

Early HIV Treatment in Infants: The Canadian Experience Img
Children (Ages 0-17)

Early HIV Treatment in Infants: The Canadian Experience

Initial results from the Canadian pediatric HIV research mentioned in a recent blog post were published in Clinical Infectious Diseases on June 9th. The paper notes that Canada's three pediatric HIV care institutions have a longstanding policy of adm...

Wrestling With the Implications of the Mississippi Case Img
Children (Ages 0-17)

Wrestling With the Implications of the Mississippi Case

Understandably, there has been extensive media coverage of the announcement that HIV has rebounded in the "Mississippi child." Although a full discussion of the implications will take time, there are some points that may be worth noting now, accordin...

Promo Image

More on the Links Between the CD4/CD8 Ratio, Immunological Perturbations, and Risk of Illness and Death

Since posting recently about studies investigating the relevance of the CD4/CD8 ratio in the antiretroviral therapy era, several new papers and presentations have provided more information on the topic. Last week in the open access journal PLoS Patho...

Promo Image
Conference Coverage

Catching Up With Pathogenesis and Cure Research From CROI 2014

In addition to studies covered in prior posts (a possible second pediatric cure case, Sangamo's gene therapy and limitations of latency-reversing agents), CROI 2014 featured a smorgasbord of presentations related to pathogenesis and cure research. We...

Better Late Than Never: Efavirenz Dose Optimization Img

Better Late Than Never: Efavirenz Dose Optimization

Research is emerging that Sustiva -- one of the drugs in Atripla, and a major culprit of neurological side effects among people who take it -- doesn't actually need to be taken at its commonly prescribed dose.

Promo Image
Tuberculosis

Fool's Errand: The Sloppy Science of the MDR-TB STREAM Trial

They should have left well enough alone. The original design of a landmark clinical trial evaluating a shortened course of treatment for multidrug-resistant tuberculosis (MDR-TB) was just what was needed to confirm its potential benefits over the Wor...

Forgotten Negatives: The Limits of Treatment as Prevention Img
Viewpoints

Forgotten Negatives: The Limits of Treatment as Prevention

There is no shortage of depressing statistics when it comes to HIV prevention in the United States: 50,000 new HIV infections annually; a 12% increase in new infections among gay and bisexual men and transgender women between 2008 and 2010; an estima...